Completely Natural
Hexamer vaccine scaffold is made of natural peptides, which can be quickly adjusted to target specific regions of a virus or variant mutation.
The Ideal Platform for Building Infectious Disease Vaccines
We believe our scalable vaccine technology has a critical role to play in future pandemics
A Unique Technology
Self-Assembling Scaffold
The Hexamer scaffold self-assembles into multi-valent, highly immunogenic particles that optimally present antigens to the immune system.
Stoichiometrically Controlled Reactions
Conjugation of antigens makes our technology unique because the reaction can be stoichiometrically controlled and used with a wide variety of different antigens to present both linear and conformational epitopes to the immune system.
Non-Immunogenic Scaffold
Our scaffold remains non-immunogenic and focuses immune responses to the peptide antigen. This is important because our scaffold contains no immunodominant epitopes to mask immune responses against conjugated antigens.
Compatible With Wide Variety of Antigen
Attaching antigens using a conjugation approach is important because the scaffold is compatible with a wide variety of targets like: peptides, small molecules, glycans and lipids.
Robust Immune Responses
When combined with a synergistic adjuvant, our vaccine technology has shown robust and durable immune responses, including a persistent depot effect predicting the potential for a single dose vaccine.
Specific Advantages of Hexamer Therapeutics Vaccine Platform
Fast
In about one week, vaccine developers can go from target protein or DNA sequence data to having candidate vaccines that are ready for immediate testing.
Stable
The vaccine is stable at room temperature for distribution and storage. Suitable for stockpiling as a lyophilized powder for very long-term storage.
Scalable
Highly scalable manufacturing because the scaffold carrier and antigenic tips are all made exclusively of natural peptides. A typical cGMP peptide manufacturer can make ~100 KG in ~6 months (~2 billion doses at 50µg each).
Powerful
Studies proved superior protection from SARS-CoV-2 (Delta) in hambsters compared to mRNA vaccines. Target cancer molecule eliminated in 28 days and a single dose conveyed high titers past 168 days in mice.
Optimal
Robust, durable immune responses that are balanced (Th1/Th2) when combined with appropriate adjuvant. We have strong evidence in preclinical trials for a persistent depot effect allowing for a single dose vaccine.
Adaptable
Ideal for addressing mutant viral strains as a suite of variant-specific antigen targets can be mounted on the scaffold and then combined for a broad ranging and highly effective vaccine.
Versatile
The self-assembling scaffold peptide can easily be modified to incorporate proprietary/patented T-cell epitopes and perfectly display a variety of antigenic targets.
Safe Components
Made entirely of natural peptides, there are no cells, no eggs, no killed virus, no large viral proteins and no biological recombinant elements are involved in the manufacturing process.
Innovative
The technology is a self-assembling, natural, peptide scaffold platform that can be armed with a variety of different antigenic targets very quickly. We are building a portfolio of IP with PCT patents filed and granted on the vaccine scaffold loaded with a variety of peptides and small molecules for use in human and animal health.
Hexamer’s Most Recent Vaccine Trials
Please contact Hexamer Therapeutics for an update on progress with infectious disease vaccines, cancer therapeutics or vaccines in animal health (swine, cattle, dogs, cats, and horses). We have license space available for a variety of infectious disease indications.